We are live on ! Find out more
INBX

Inhibrx, Inc. Common Stock

Delisted

INBX was delisted on the 29th of May, 2024.

55 hedge funds and large institutions have $326M invested in Inhibrx, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 12

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

8% more funds holding

Funds holding: 5155 (+4)

36% less capital invested

Capital invested by funds: $513M → $326M (-$187M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
55
Holders Change
+4
Holders Change %
+7.84%
% of All Funds
0.97%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
9
Increased
24
Reduced
12
Closed
5
Calls
Puts
Net Calls
Net Calls Change

INBX Hedge Fund Activity: Q1 2021 in Review

55 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q1 2021, worth a combined $326M — down 36% from $513M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new INBX positions and 5 closed out — a net gain of 4 holders — while 24 added to existing stakes and 12 trimmed.

The largest buyer was Wellington Management Group, opening a new position worth an estimated $57.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $70.2M sold.

  • 55 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q1 2021, up from 51 in Q4 2020.
  • Funds reported $326M of Inhibrx, Inc. Common Stock stock for Q1 2021, down 36% quarter-over-quarter.
  • 9 funds opened new Inhibrx, Inc. Common Stock positions in Q1 2021 and 5 closed out, a net change of +4 holders.
  • The largest Inhibrx, Inc. Common Stock buyer in Q1 2021 was Wellington Management Group, an estimated $57.7M added.
  • The largest Inhibrx, Inc. Common Stock seller in Q1 2021 was RA Capital Management, an estimated $70.2M sold.

Based on aggregated 13F filings for Q1 2021.